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OVERVIEW
This presentation will discuss our current understanding of:
• Impact of space radiation on medication stability
We will further discuss opportunities for improved scientific 
understanding and research for future exploration spaceflight
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PHARMACEUTICAL 
STABILITY
Radiation
• Beyond LEO, the most important sources of space 
radiation consist of galactic cosmic rays (GCR), and 
Solar Particle Events (SPE).
• GCR
• Dose-rates ~0.3 mGy / day from GCR
• SPE
• Modeled intravehicular dose-rates: 0 – 2800 mGy / hr during 
large SPE in interplanetary space
• Shielding can protect crewmembers AND pharmaceuticals
Pharmaceutical Stability: Radiation
Pharmaceutical Stability
• Loss of drug stability caused by any alteration of physical
or chemical properties can result in: 
- changed:
• Appearance
• Dosage form physical attributes and uniformity
• Potency
• Excipient composition
- or promoted:
• Excipient-active ingredient interactions
• Toxic degradation
Pharmaceutical Stability
• To test for stability:
– Concentration of Active Pharmaceutical Ingredient (API)
o Acceptable ± limits defined by US Pharmacopoeia
– API Release Characteristics
o Dissolution (e.g. tablets, capsules) / Diffusion (e.g. ointments, creams)
– Presence of degradation products
o Some known / toxic products have USP-determined limits
– Visible alteration of physical appearance
Stability Evidence: Flown Studies
Altered 
Medication
Unaltered 
Medication
References
* Drug tested only for Vit B API
** Drug would fail by today’s API standard
† drug had unidentified degradant product
• Risk of Radiation:
– High-intensity electromagnetic radiation:
o May cause significant loss of API – can reduce therapeutic effect
o May initiate formation of degradation products
– Is radiation contributing to the alterations observed in 
spaceflight? Or are other environmental factors?
Pharmaceutical Stability: Radiation
Photolability
Reference Doses (GCR, SPE)
Du et al. 2011 Study Data
Environmental Conditions
Ground Control
Flight Samples• Flight vs. Ground Controls:• No significant difference in 
temperature 
• Minor alterations of 
humidity 
• Significant difference in 
radiation exposure:
Du et al. 2011 Study Data
Ground Control
Flight Samples
Du et al. 2011 Study Data
• Difficult to emulate space environment on Earth
– Limitations:
• Dose
• Dose-rate
• Type of exposure
• Intravehicular / intrapackaging environment
• No well-characterized validation studies (ground-to-space)
Terrestrial Evidence: Radiation
Supplemental Discussion: 
Space Environment Emulation
Terrestrial Evidence: Radiation
• Few terrestrial irradiation 
studies of pharmaceuticals
– All show at least some 
medications with API alteration
– Study irradiation much higher 
than even cumulative mission 
doses
– Minimal comparative study 
(Chuong)
– Difficult to determine 
significance of irradiation from 
limited data
Supplemental data: BCM, NSRL, Chuong
Terrestrial Evidence: Radiation
Clavulanate API % content by dose received Promethazine API % content by dose received
Why might drug stability following exposure to high-dose radiation not necessarily 
translate to drug stability following exposure to low-dose radiation?
Terrestrial Radiation: Conclusions
• Uncertainty regarding space radiation 
– Data points do not align with modeling projections 
that suggest little-to-no impact of radiation on drug 
stability
– Terrestrial radiation studies have been limited
– Minimal study of comparative effects of space 
radiation to ground analog radiation
CONCLUSIONS
AND
RECOMMENDATIONS
Conclusions
1. We have insufficient data collection to understand the effect of the space 
environment on medications used during missions today
2. Our current understanding of pharmaceutical stability suggests that the 
interplanetary radiation environment may have a substantial impact on 
medication stability for long-duration exploration missions
To provide safe and effective medications for exploration spaceflight, we need to 
balance resources available with a standard of acceptable scientific evidence 
sufficient to characterize the risk
Recommendations
1. Crew tracking of pharmaceutical usage, effectiveness, and side 
effects should be encouraged and streamlined
2. Pilot research projects regarding initial characterization of the 
radiation-related stability issues that may be encountered in flight 
should be encouraged to build a foundational database from 
which the need for future, more detailed investigations can be 
evaluated. 
3. NASA and industry / academic partners should actively pursue 
spaceflight exposures of medications to characterize with the best 
available evidence the environmental impact on pharmaceuticals 
in upcoming missions.  
QUESTIONS?
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Limitations of Terrestrial Radiation Research
• Dose – cumulative mission dose delivered over a matter of minutes
• Dose-rate – Significantly higher dose-rate in terrestrial studies or radiostability
analyses
• Altered energy delivery = altered chemical reactions, short-term dosing = no propagation 
of reaction over time; may alter free-radical generation or exhaustion
• Type of exposure – single ion does not emulate the complexity of the space 
environment or the varied energy transfers of different ions
• Intravehicular / intrapackaging – added spallation (scatter) ions may alter chemistry 
or reactivity of exposed drugs
• Hydrolysis vs. Direct – historically focused on water-based drugs re: increased 
production of free radical (oxygen species). 
• Direct impact to solid/powder drug lattice may trap free radicals, directly catalyze 
chemical reaction, or alter excipient structure
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Terrestrial Evidence: Radiation
Chuong et al. 2011
• Multivitamins irradiated, analyzed for Vit B content 
only
• Large range in API allowed (90-150%)
• Significant change in B1 in all irradiated samples and 2 
controls
• API decrease not seen as dramatically in ISS flown 
samples
• Unclear significance
Back to presentation
Terrestrial Evidence: Radiation
% STDEV % STDEV % STDEV % STDEV
Amoxicillin 875 mg 111.5 0.16 104.8 1.49 101.5 NR 109.1 NR 90-120
Clavulante 125 mg 96.9 0.1 88.1 0.09 83.3 NR 94.5 NR 90-120
98.2 NR 94 NR NR NR 96.3 NR 95-110
98.3 0.26 96.8 NR 90.3 1.08 93.7 NR 95-110
97.6 0.53 95.8 NR 89.5 0.08 95.6 NR 95-110
Sulfamethoxazole (800 mg) 97.9 1.27 94.2 NR 93.1 0.37 96 NR 93-107
Trimethoprim (160 mg) 96.8 1.81 87.9 NR 81.4 3.17 93.6 NR 93-107Bactrim®  Tablets
0.017
PERCENT LABELED CONTENT
NR:  No result provided in report
N/A
Promethazine 25 mg Tablets
Promethazine 50 mg/ml Inj. Solution
Promethazine 25 mg Suppositories
Augmentin® Tablets 
IRRADIATION DOSE (KGy)
DRUG FORMULATION
9.36 35.8
Gamma
USP CONTENT 
REQUIREMENT
ControlRADIATION SOURCE Nucleon Titanium
API content data analysis, BCM Simulation Radiation Study, L. Putcha et al, 2006
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Control
N/A Iron Proton Iron Proton Iron Proton
USP API CONTENT 
REQUIREMENT
98.8 96.2 96.7 94.7 95.2 94 94.8 90-110
100.2 100.4 97.3 97.8 98.5 98.6 96.0 98-102*
Amoxicillin 875 mg 116.1 116.2 115.6 109.8 112.0 115.9 114.4 90-120
Clavulante 125 mg 93.5 88.6 88.1 79.4 48.0 83.4 78.2 90-120
96.9 96 96.1 95.9 94.5 96.1 96.4 90-110
99 96.4 94.8 94.6 91.7 95 94.8 90-110
99.1 100.9 100.3 100.1 99.3 100.2 99.5 90-110
99.5 98.6 98.8 98.8 98.9 98.7 98.2 90-110
101.4 102.3 102.5 102.3 102.6 102.6 102.8 90-110
94.1 96.6 93.4 93.5 94.2 95.3 94.4 90-110
100.5 99.6 100.3 100.2 99.7 100.3 99 90-110
98.0 96.2 96.6 94.2 94.5 92.5 93.9 90-110
97 96.2 97.3 96.1 93.9 95.3 96.3 95-110
99.2 99.6 97.8 97.3 98.4 98.7 98.8 95-110
103.5 102.3 102.1 103.1 102.9 103.3 103.6 95-110
100.8 99.6 100.4 98.7 98.8 96.9 97.7 95-115
98.6 97.7 98.0 96.8 97.1 95.9 96.5 90-110
100.5 100.4 100.1 100.2 99.8 100.2 99.8 90-110
Sulfamethoxazole (800 mg) 100.7 97.5 100.5 95.9 97.5 96.2 96.5 93-107
Trimethoprim (160 mg) 101.5 98.2 101.3 96.5 98.5 97.1 97.3 93-107
0.1 10 50IRRADIATION DOSE (Gy)
DRUG FORMULATION % Labeled API Content
Ciprofloxacin 500 mg Tablets
Acetaminophen 325 mg Tablet
Atorvastatin 10 mg Tablets
Clotrimazole 1% Cream
Augmentin® Tablets 
* No USP monographic API content requirements available at time of analysis; current requirement shown
Promethazine 25 mg Suppositories
Riboflavin 100 mg tablets
Silver Sulfadiazine 1% Cream
Temazepam 15 mg Capsules
RADIATION ION SPECIES
Bactrim®  Tablets
Ibuprofen 400 mg Tablets
Levothyroxine 25 mcg Tablets
Mupirocin 2% Ointment
Phenazopyridine 100 mg Tablet
Promethazine 25 mg Tablets
Promethazine 50 mg/ml Inj. Solution
Ciprofloxacin 0.3% Ophthalmic Solution 
Ciprofloxacin 0.3% Ophthalmic Ointment 
API content data analysis, NSRL Simulation Radiation Study, L. Putcha et al, 2006
Terrestrial Evidence: Radiation
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Dose-Dependent Stability
• Low dose = low nanomolar ion concentration
– May alter pH more than higher doses
 Dose changes type and concentration of free radicals produced
– Can alter reactivity or affect chemical reaction progression
– Electron spin resonance (detects free radicals) evidence supports
• High dose rate may increase radical consumption
– Radicals interact with each other at higher doses
– Low dose paradoxically frees more radicals for chemical interactions with drug 
substrate
• Solid / powder drug formulations
– Increased radical trapping in excipient lattices at lower doses
– Longer free radical presence in solids / powders exposed to lower doses
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Medication Use Evaluation – LSAH Data
Data: Expeditions 1 through 40 
(~107.5 months)
• 43 unique crewmembers (7 women, 
36 men)
• 790 total reported medication uses
Data: Expeditions 21 through 40 
(63.5 months)
• 20 unique crewmembers (5 women, 
15 men)
• 462 total reported medication uses
Bayuse- On Orbit MUE Summary
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Pharmacotherapeutics: Adverse Effects
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Bayuse- On Orbit MUE Summary
• PMC tool doesn’t 
‘ask’ to capture 
this information.
• Adverse effects 
self-reported
• A Zero in this 
graph does not 
mean that there 
weren’t adverse 
effects, only 
means there is 
no 
documentation.
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Potential Drug-Drug Interactions
Bayuse- On Orbit MUE Summary
• Potential DDI
• Medications taken 
concurrently during the 
reporting period
• 28 of the 29 due to 2 
sleepers reported use 
within the same 
reporting period.
• Interactions between 
different classes of drugs
• Underestimated: the fidelity of 
data doesn’t support this level 
of review
• Multiple days of possible 
interactions within each 
reporting period
• Lack of dosing specificity as 
a contributing factor (i.e., 
timing of drugs taken during 
the reporting period) 
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Dose Tracker Insights
• Dose Tracker pilot project: 
• Collected data on 6 crewmembers during ISS missions
• As of February 2017, DT collected over 224 weeks of medication 
usage data 
• 128 weeks inflight, 96 weeks on the ground
• >5800 recorded medication entries (3049 inflight, 2717 ground)
• Average of 961 entries per subject (453 inflight, 508 ground). 
• Inflight average of 453 medication entries per subject
• 20x increase over average 23.1 / CM reported Exp 21-40
• 60x increase over average 7.6 / CM reported Exp 1-20
• 49 reports of no medication use in a given week of data collection
• POSITIVE confirmation of no medication use
• Previous efforts rely on possibly incorrect assumption that no report = 
no medication use
Back to presentation
Barger 2014: Med Usage and Reporting
Roughly three-quarters of shuttle crew members 
reported taking sleep-promoting drugs in-flight 
(table 1). 
• Use of sleep drugs was reported on 500 
(52%) of the 963 in-flight nights, with two 
doses of sleep drugs on 87 (17%) of 500 
nights on which such drugs were taken
• Use of sleep drugs was reported on 60% of 
nights before extravehicular activities (table 
1).
Of the 21 ISS crew members, more than a third 
(n=8) declined to answer the question about drug use 
on the sleep log at some point during the mission, 
which prevented the question being asked in future 
logs.
• Three of those eight participants indicated sleep 
promoting drug use in the mission before 
declining to answer the question. 
• Sleep drugs were reported as being used on 96 
(11%) of 852 sleep logs. On 18 (19%) of 96 
days when sleep-promoting drugs were used, 
two doses were reported.”
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Physiology: References
• Fluid shifts
• Altered volume of distribution
• Guyton and Hall 2006
• Hargens and Watenpaugh 1996
• Diedrich 2007
• Montgomery 1993
• Drummer 1993
• Leach 1991
• Intracellular fluid alteration
• Altered metabolism, altered drug uptake and 
clearance
• Leach 1996
• Altered plasma protein concentration
• Altered free drug concentration
• Altered renal/hepatic clearance
• Rice 2001
• Larina 2017
• Cell Membrane Permeability
• Altered drug distribution and uptake
• Sumanasekera 2007
• Hepatic metabolism
• Altered hepatic blood flow
• Altered hepatic enzyme expression
• Racine 1992
• Hargrove 1985
• Hollander 1998
• Merrill 1992
• Merrill 1990
• Merrill 1987
• Gut motility and absorption
• Altered gastric emptying from SMS or 
medications to address SMS
• Increased GI wall edema = decreased 
absorption
• Faster and more variable intestinal transit rate
• Rowland 1975
• Katzung 2007
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Stingl 2015: Medications with Genetic 
Polymorphisms
• Crewmembers may have 
altered responses to 
medications due to 
individual genetic 
polymorphisms
• May suggest benefit of 
tailoring pharmacy to 
individualized response
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Cintron 1987: PK / PD
Acetaminophen / Scopolamine
• Two flown studies 
(acetaminophen – 5 subjects, 
scopolamine – 3 subjects)
– Saliva sample collection by 
convenience – no time consistency, 
variable results
• Crewmembers demonstrated 
altered PK / PD in flight – in 
general:
– Early mission: faster absorption, 
faster peak concentration, more 
rapid clearance
– Later mission: slower absorption, 
lower peak
Mission Day 3 Mission Day 4
Mission Day 1-2 Mission Day 2-3
Acetaminophen
Scopolamine
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Boyd 2009: Promethazine PK / PD
• Unpublished study
• 6 crewmembers, took 1 dose of promethazine on mission day 1
• Monitored saliva concentration for 72h
• Variable sample retrieval (see graphs below)
• Difficult to interpret; overall, higher peak concentration, shorte  
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Putcha 1999: Anecdotal Reporting
• Anecdotal reporting of “not effective” and “mildly effective” medications by 
crewmembers
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Barger 2014: Anecdotal Reporting
• Anecdotal reporting of use of more than one drug or dose for sleep-
promoting medications
• On the ISS, sleep drugs were reported as being used on 96 (11%) of 852 
sleep logs. 
– On 18 (19%) of 96 days when sleep-promoting drugs were used, two doses were 
reported.
• Seventy-eight percent of shuttle mission crewmembers (61/78) reported 
taking sleep medications inflight. 
– Sleep medications use was reported on 52% of the inflight nights (500/963) 
– 2 doses of sleep medication on 17% of nights that sleep medications were taken
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Animal Model Validation: Enzyme Activity
• Carcenac 1999: validation study of hindlimb suspension vs. flown 
animals, studied cGMP production
– Significant increase in basal choroid cGMP levels after flight
– Suspended rats demonstrate atrial naturetic pepctic (ANP)-dependent cGMP
increase – NOT SEEN in flown animals
– Suggests poor correlation between spaceflight and suspension model
• Racine 1992: validation study of hepatic cellular morphology
– Flown cells larger, increased glycogen and lipid storage, than suspended animals
– Decreased Kupffer cells (decreased defense capacity) in flown animals
– Suggests poor correlation between spaceflight and suspension model
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• Additional reports of therapeutic failure
– Antibiotic cultures
• E. coli: demonstrated increased resistance to colistin, kanamycin (3 studies 
1985, 1 study 1994)
– Additional concern for dihydrostreptomycin – inconclusive resistance 
studies
• S. aureus: demonstrated increased resistance to oxacillin, chloramphenicol
• In some cases required DOUBLE the antibiotic dose to meet antibiotic 
effect
Spaceflight Evidence: PK/PD
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Bacterial Antibiotic Response
• Tixador 1985:
– Flown cultures of Staphylococcus aureus and Escheria coli demonstrated increased 
antibiotic resistance (increased “minimal inhibitory concentration” of antibiotics) 
Back to presentation
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• Human Flown
• Cintron, NM, Putcha, L, Vanderploeg, JM. In-flight pharmacokinetics of acetaminophen 
in saliva. NASA Johnson Space Center: National Aeronautics and Space 
Administration; 1987. TM No: NASA/TM-1987b-58280.
• Cintron, NM, Putcha, L, Vanderploeg, JM. In-flight salivary pharmacokinetics of 
scopalamine and dextramphetamine. NASA Johnson Space Center: National 
Aeronautics and Space Administration; 1987. TM No: NASA/TM-1987-58280.
• Boyd J, Wang Z, Putcha L. Bioavailability of Promethazine during Spaceflight. NASA 
Johnson Space Center: National Aeronautics and Space Administration; 2009. TM No: 
NASA/TM-2009-01322.
• Human Anecdotal Reports
• Putcha L. Pharmacotherapeutics in space. J Gravitational Physiol J Int Soc
Gravitational Physiol 1999; 6:P165-168. (Anecdotal only)
• Barger LK, Flynn-Evans EE, Kubey A, et al. Prevalence of sleep deficiency and use of 
hypnotic drugs in astronauts before, during, and after spaceflight: an observational 
study. Lancet Neurol 2014; 13: 904-12
Spaceflight Evidence:  PK/PD
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• Rodent Flown
• Hargrove JL, Jones DP. Hepatic enzyme adaptation in rats after space flight. The Physiologist 1985; 28:S230. 
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enzymes. Am J Physiol-Regul Integr Comp Physiol 1987; 252:R222–6. 
• Merrill AH, Wang E, LaRocque R, Mullins RE, Morgan ET, Hargrove JL, et al. Differences in glycogen, lipids, and 
enzymes in livers from rats flown on COSMOS 2044. J Appl Physiol Bethesda Md 1985 1992; 73:142S–147S.
• Moskaleva, N., A. Moysa, et al. Spaceflight Effects on Cytochrome P450 Content in Mouse Liver. PLoS ONE 2015; 
10(11): e01142374
• Jonscher KR, Alfonso-Garcia A, Suhalim JL, Orlicky DJ, Potma EO, Ferguson VL, et al. Spaceflight Activates Lipotoxic
Pathways in Mouse Liver. PLoS ONE 2016; 11(5): e0155282
• Blaber, E. A., M. J. Pecaut, et al. "Spaceflight Activates Autophagy Programs and the Proteasome in Mouse Liver." Int
J Mol Sci 2017; 18(10): 2062.
• Bacterial Culture Flown
• Lapchine L, Moatti N, Gasset G, et al. Antibiotic activity in space. Drugs Exptl Clin Res 1985; 12 (12): 933-8.
• Tixador R, Richoilley G, Gasset G, et al. Preliminary results of Cytos 2 experiment. Acta Astronaut, 1985; 12(2) 131-4.
• Tixador R, Richoilley G, Gasset G, et al. Study of minimal inhibitory concentration of antibiotics on bacteria cultured in 
vitro in space (Cytos 2 experiment). Avit Space Environ Med 1985; 56(8): 748-51.
• Tixador R, Gasset G, Eche B, et al. Behavior of bacteria and antibiotics under space conditions. Aviat Space Environ 
Med 1994; 65(6): 551-6.
Spaceflight Evidence:  PK/PD
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• Human Bedrest
• Feely J, Wade D, McAllister CB, Wilkinson GR, Robertson D. Effect of hypotension on liver blood flow and lidocaine
disposition. N Engl J Med 1982; 307:866–9. 
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Eur J Clin Pharmacol 1986; 30:731–4. 
• Saivin S, Pavy-Le Traon A, Cornac A, Güell A, Houin G. Impact of a four-day head-down tilt (-6 degrees) on 
lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. J Clin Pharmacol 1995; 35:697–704. 
• Rodent Hindleg Suspension
• Brunner LJ, Bai S, Abdus-Salaam H. Effect of simulated weightlessness on phase II drug metabolism in the rat. 
Aviat Space Environ Med 2000; 71:899–903. 
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6:17–24. 
• Racine RN, Cormier SM. Effect of spaceflight on rat hepatocytes: a morphometric study. J Appl Physiol Bethesda 
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rats." Int J Clin Exp Med 3(1): 48-54.
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